Ipamorelin Side Effects: Real Risks vs Myths

Ipamorelin is often described as the "cleanest" GHRP — and for good reason. Its selective mechanism avoids the cortisol and prolactin elevation associated with older GHRPs like GHRP-6 and GHRP-2. This article separates the genuinely documented side effects from the myths that have spread from inaccurate comparisons to other compounds.

Why Ipamorelin Has a Cleaner Profile Than Other GHRPs

GHRP-6 and GHRP-2 (earlier generation GH releasing peptides) activate the ghrelin receptor broadly, which includes pathways that elevate cortisol, ACTH, and prolactin. Ipamorelin was specifically developed to be highly selective for GH release only, minimising off-target receptor activation.

This selectivity is documented in the original Ipamorelin studies (Raun et al., 1998) and is the primary reason it became the preferred GHRP in research applications — and why the side effects associated with older GHRPs don't apply in the same way.

Real Reported Side Effects

Water retention

Common at higher doses

Mild water retention — particularly in the face and extremities — is the most commonly reported side effect. Typically dose-dependent and resolves after cycle completion. Most pronounced with CJC-1295 With DAC stacks.

Mild fatigue / drowsiness

Common (first 1–2 weeks)

Some researchers report initial fatigue during the first 1–2 weeks of use. Hypothesised to be related to the GH-sleep cycle interaction. Usually resolves as the body adapts.

Headache

Uncommon

Mild headaches reported occasionally, particularly at higher doses or when insulin sensitivity is affected. Staying well hydrated reduces incidence.

Increased hunger

Mild — less than other GHRPs

Ipamorelin produces less hunger stimulation than GHRP-6 or GHRP-2. The ghrelin receptor activation causes some appetite increase, but it is significantly blunted compared to other GHRPs.

Injection site redness/discomfort

Common

Localised redness and mild soreness at the injection site. Standard for any SubQ peptide injection. Resolved by rotating sites.

Tingling (extremities)

Uncommon

Occasionally reported, particularly with prolonged use. May be related to fluid shifts or mild IGF-1 elevation. Not associated with nerve damage in animal studies.

Side Effect Myths — Debunked

Myth: "Ipamorelin raises cortisol significantly"

FALSE — this is one of Ipamorelin's key advantages over GHRP-6 and GHRP-2. Studies specifically show that Ipamorelin does NOT significantly elevate cortisol at typical doses. It was designed to be selective for GH release without the cortisol/ACTH activation seen with other GHRPs.

Myth: "Ipamorelin raises prolactin significantly"

FALSE at normal doses — similar to cortisol, selectivity for GH over prolactin is considered one of Ipamorelin's defining characteristics. Prolactin elevation is minimal compared to GHRP-2 or Hexarelin.

Myth: "Ipamorelin causes gynecomastia"

No evidence of this in animal studies or research community observation at typical doses. The low prolactin elevation profile means this concern doesn't apply to Ipamorelin in the way it might for compounds with significant prolactin elevation.

Myth: "Ipamorelin suppresses natural GH production"

No evidence of suppression in published studies. Unlike exogenous HGH (which does suppress the pituitary), GH secretagogues work through the body's own pituitary — and cycling off restores natural baseline function.

Who Should Not Use Ipamorelin

Active cancer or cancer history

GH elevation is a theoretical concern for cancer growth. The IGF-1 pathway that GH activates has known associations with tumour proliferation.

Insulin-resistant or diabetic individuals

GH can reduce insulin sensitivity. People with metabolic dysfunction or diabetes who use GH secretagogues without medical supervision risk worsening glucose control.

Pregnancy or breastfeeding

No safety data. Avoid all unapproved research compounds in pregnancy.

Under 21 / still in development

Manipulating GH in individuals whose natural GH axis is still fully active and optimising may produce unpredictable downstream effects.

Ipamorelin — Research Grade

Available from Base Peptides with third-party CoA.

View at Base Peptides

Research use only. Ipamorelin is not FDA-approved for human use. Side effects described are anecdotal or from animal studies. Not medical advice.

GH Peptides Guides

→ CJC-1295 + Ipamorelin Dosage Protocol → Ipamorelin vs CJC-1295 Comparison → Best Time to Take CJC-1295 → CJC-1295 vs Sermorelin → Can You Take CJC-1295 Alone?→ How GH Peptides Work → GHRH vs GHRP Peptides